The Gross to Net Team, part of the US Therapeutics Pricing organization manages sales reporting of ~$70 billion rebates/discounts and ~$44 billion annual net sales.  Quarterly reserve reconciliation of ~$16 billion in rebates and contra-receivable balances.   Responsible for related systems/systems issues surrounding sales reporting and reserve reconciliation and analysis.

The Finance Director, GTN Pricing Reserve & Reporting will be responsible for supporting internal and external auditor deliverables, oversee the GTN Reserve of $16 billion and drive GTN Kernel system enhancements.

This position reports to the Director, GTN Pricing US Therapeutics.

Main Roles/Responsibilities:

Responsibilities will include, but are not limited to:

• Lead the quarterly process of reviewing sales reserve reconciliations and analysis of ~$16 billion in rebate reserves, as well as contra-receivables accounts.
• Lead or support the GTN reviews with leadership and external auditors.
• Understand the market dynamics and PBM/340b impact including scrubbing.
• Collaborate with Price Forecasting monthly; analyze variances and recommend necessary adjustments.
• Review journal entries and ensure timely Blackline approvals.
• Lead internal and external quarterly and annual audits and reviews and sign off team’s SOX controls and IPE (Information Provided by Entity) shared with auditors.
• Supervise, mentor, and develop a staff of four direct reports and two indirect reports.
• Coordinate all team monthly task and responsibilities. Ensure timely guidance.
• Coordinate with cross-functional teams (e.g., contracting, government, price forecasting) to ensure alignment and provide critical information to all management levels.
• Assure adequate controls are designed, implemented, and monitored in the GTN space
• Serve as the internal Subject Matter Expert on Gross-to-Net Balance Sheet topics; deliver training and guidance to business partners as needed.
• Expert in Kernel system. Ensure full integration of Channel Summary and PBM information and lead system enhancements